RecruitingNot ApplicableNCT04368039

Normobaric Oxygen Therapy for Individuals With First-Episode Psychosis


Sponsor

Nicholas Breitborde

Enrollment

20 participants

Start Date

Dec 4, 2019

Study Type

INTERVENTIONAL

Conditions

Summary

Single-blind, randomized controlled trial of normobaric oxygen therapy among individuals with first-episode psychosis: Effects on symptomatology and cognition.


Eligibility

Min Age: 15 YearsMax Age: 35 Years

Plain Language Summary

Simplified for easier understanding

This study is testing whether breathing high levels of oxygen in a normal-pressure environment (normobaric oxygen therapy) can improve symptoms in people who have recently experienced their first episode of psychosis. The idea is that oxygen therapy may support brain healing and improve thinking and mood in the early stages of psychotic illness. **You may be eligible if:** - You are 15 to 35 years old - You have been diagnosed with a schizophrenia-spectrum disorder or a mood disorder with psychotic features - Your first psychotic episode began less than 5 years ago - You estimate average intelligence or above (IQ estimated above 70) - You are a non-smoker and have not smoked for the past 6 months - You have no thoughts of suicide or self-harm in the past month **You may NOT be eligible if:** - You have a history of intellectual disability - You have been smoking recently (within the last 6 months) - You have active suicidal thoughts or behavior - You have medical conditions that may be worsened by supplemental oxygen therapy Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICENormobaric Oxygen

40% FiO2 for 4 weeks

DEVICEPlacebo

21% FiO2 for 4 weeks


Locations(1)

Harding Hospital

Columbus, Ohio, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04368039


Related Trials